<May 17, 2023 Beijing> Vision China 2023, one of the largest academic conferences in the field of eye health, was grandly inaugurated in Beijing. HTDK was invited to participate in this prestigious event, and CEO Teresa delivered a keynote speech titled “From 0 to 1: A Comprehensive Analysis and Outlook on the Commercialization of Ophthalmic Products.” She joined leaders from regulatory authorities, experts, scholars, heads of medical institutions, and top industry executives to discuss three major trends in the domestic and international ophthalmic markets and HTDK’s outstanding practices in building an innovative product commercialization system and expanding into the global market.

On May 17, 2023, the 10th Vision China International Forum on Innovation and Development in Visual Health officially opened at the Shougang Park in Beijing. The opening ceremony was hosted by Lü Fan, Director of the National Clinical Research Center for Eye Diseases, with a welcoming speech from Qu Jia, Chairman of the conference’s academic committee.

Originating in Wenzhou, Vision China is inherently innovative. Over ten years, it has become a prestigious platform for academic exchange in ophthalmology and optometry, boasting the largest attendance and greatest influence among similar conferences in China.

As China’s largest provider of commercial solutions for ophthalmic medical devices, HTDK was invited to participate in the 2023 International Forum on Clinical Innovation and Translation in Ophthalmology (iChina2023) and delivered a keynote address.

Teresa analyzed the macro market environment and policies of the ophthalmic sector, stating, “Consumerization, youth and elderly demographics, and the domestic production of mid-to-low-end equipment are the three major trends in the domestic ophthalmic field. In the international market, products like glaucoma MIGS and dry eye treatments have been recent hotspots.”

Sharing HTDK’s extensive experience in registration and commercialization of innovative products, Teresa discussed different registration paths for 136 types of ophthalmic products, how to quickly achieve market entry through innovative medical device pathways, and exemptions from VBP and DRGs insurance restrictions. She also delved into key aspects of ophthalmic product commercialization, such as market entry and patient education, drawing on HTDK’s best practice cases.

For nearly 20 years, HTDK has deeply rooted itself in China’s ophthalmic field, covering 23 provinces and core ophthalmic chain hospitals nationwide. As the largest provider of commercial solutions for ophthalmic medical devices in China, HTDK helps innovative ophthalmic companies and products quickly enter the Chinese market and achieve efficient market coverage, aiming to be the accelerator for ophthalmic product commercialization.

The forum concluded successfully, receiving unanimous acclaim from experts and companies present. Teresa remarked, “Innovation and development in ophthalmic clinics and commercialization require not only continuous breakthroughs in technology and products but also the formation and improvement of an ophthalmic ecosystem, unifying industry, academia, research, and commerce. HTDK is dedicated to accelerating the marketization of innovative ophthalmic products. Our platform and ecosystem construction and operation continuously expand HTDK’s network in the ophthalmic field. We will actively invest in the construction of the ophthalmic industry ecosystem, fostering win-win cooperation with ecosystem partners.”

iChina2023 attracted experts from ophthalmic hospitals, the ophthalmic medical industry, investment institutions, and more. Renowned entities like Wenzhou Medical University Eye Hospital, Aier Eye Hospital, Remegen Capital, EagleEye Technology, Beijing Institute of Technology, Zhejiang University Second Affiliated Hospital, and Essilor shared their insights on ophthalmic innovation from bench to bedside.

In addition to experience sharing by industry practitioners, the event featured presentations from 11 innovative ophthalmic pharmaceutical and medical device companies. These companies focused on unmet clinical needs, particularly in areas like macular degeneration, glaucoma treatment, and pediatric strabismus and amblyopia treatment.

HTDK discussed the commercialization possibilities and paths for these products with the companies and presented awards to the winning teams.

In the future, HTDK’s commercialization team will maintain long-term business communication with these innovative ophthalmic product companies at various stages of their development, jointly exploring pathways for commercialization in China and accelerating the marketization process of innovative ophthalmic products.